Adipogenic Differentiation of Human Mesenchymal Stem Cells Derived from Fetal Bone Marrow Using Rosiglitazone

Resumo

Protocols of adipogenic differentiation for mesenchymal stem cells (MSC) are mostly based on addition of various inducers, including rosiglitazone, a. specific agonist of PPARG facilitated the differentiation in this lineage. Rosiglitazone was not used for induction of adipogenic differentiation of fetal MSC from bone marrow (fMSC-BM). Here we described adipogenic differentiation induced by rosiglitazone in fMSC-BM (FetMSC). We found that the number of differentiated cells was 31.0 ± 1.9% (Oil Red O staining n = 1121). Expression of PPARG gene, a key adipogenic regulator, increased during differentiation. It is demonstrated that fMSC-BM generated adipocytes in the differentiation medium with rosiglitazone.